Immunocamouflaged red blood cells (RBC) are produced by cell surface derivatization with methoxypolyethylene glycol (mPEG). These immunologically attenuated cells may reduce the risk of allosensitization in chronically transfused patients. To characterize the effects of differing linker chemistries and polymer lengths, RBC were modified with cyanuric chloride activated mPEG (C-mPEG 5 kDa), benzotriazole carbonate methoxyPEG (BTC-mPEG; 5 or 20 kDa) or Nhydroxysuccinimidyl ester of mPEG propionic acid (SPA-mPEG ; 2, 5 or 20 kDa). Biophysical methods including particle electrophoresis and aqueous two-phase polymer partitioning were employed to compare the PEG derivatives. While CmPEG was faster reacting, both BTC-mPEG and SPA-mPEG gave comparable findings after 1 h. Both PEG surface density and molecular mass had a large effect on RBC surface properties. Proportional changes in electrophoretic mobility and preferential phase partitioning were achieved by increasing either the quantity of surface PEG or the PEG molecular mass. In addition, two-phase partitioning may provide a means for efficiently removing unmodified or lightly modified (hence potentially immunogenic) RBC in the clinical setting. Furthermore, mPEG modification significantly inhibits cellĉ ell interaction as evidenced by loss of Rouleaux formation and, consequently, sedimentation rate. Importantly, BTCmPEG 20 kDa RBC showed normal in vivo survival in mice at immunoprotective concentrations (up to 2 mM). ß
Introduction
Methoxypolyethylene glycol (mPEG) is a neutral, non-toxic polymer that has been covalently grafted to proteins, biomaterials and cell surfaces as a means of improving biocompatibility and reducing immunological recognition. Examples of PEG-modi¢ed agents include therapeutic proteins such as interleukin 2 for anti-tumor e¡ects [1] , streptokinase for anti-thrombosis [2] , liposomes for enhanced drug and gene delivery [3] and, most recently, mPEG-derivatized erythrocytes and lymphocytes [4^6] .
mPEG-erythrocytes have been previously characterized and were found to be morphologically and functionally normal and, at immunoprotective levels, to have normal in vivo survival in mouse models.
More importantly, mPEG modi¢cation signi¢cantly reduced the antigenicity of human red blood cells (RBC) with respect to non-ABO blood group antigens and dramatically diminished the immunogenicity of allogeneic and even xenogeneic RBC in mouse models [4, 5] . As a consequence of this immunocamou£age, mPEG-modi¢ed RBC may signi¢cantly attenuate the risk of alloimmunization for patients requiring chronic RBC transfusions such as patients with sickle cell anemia and thalassemias. This is particularly important since as many as 35% of individuals with sickle cell disease or thalassemias exhibit clinically signi¢cant alloimmunization to non-ABO antigens [7, 8] . In this clinical setting, the immunocamou£aged mPEG-RBC would be most bene¢cial in providing a safe, functional transfusion product.
To date, the majority of studies on PEGylated RBC have employed cyanuric chloride activated mPEG (C-mPEG) with a molecular mass of 5 kDa. However, because both the density of attached PEG as well as the mPEG chain length have been hypothesized to alter the e⁄cacy of the immunocamou£age [4, 9] , we have assessed alternative mPEG derivatives of varying molecular mass. Like C-mPEG, both mPEG-benzotriazolyl carbonate (BTC-mPEG; 5 and 20 kDa) and mPEG succinimidyl propionate (SPA-mPEG; 2, 5 and 20 kDa) react predominantly with the O-amino groups of lysine residues and to a lesser extent with amino-terminal groups in proteins. However, unlike C-mPEG which introduces a triazine ring between mPEG and the protein, BTC-and SPA-mPEG attach mPEG to the target in the form of a stable amide bond. Utilizing these di¡erent derivatives of mPEG, the e⁄ciency of the PEG-RBC linkage reaction and the e⁄cacy of immunocamou£age were assessed.
Materials and methods

Blood collection
Following informed consent, whole blood was drawn from normal healthy volunteers into heparin Vacutainer tubes. Erythrocytes were obtained by washing three times with saline. Murine RBC were collected in heparinized syringes from Balb/c mice via cardiac bleed.
PEG derivatives
BTC-mPEG (5 and 20 kDa) and N-hydroxysuccinimidyl ester of mPEG propionic acid (SPA-mPEG; 2 and 20 kDa) were obtained from Shearwater Polymers (Huntsville, AL, USA). SPA-mPEG 5 kDa was purchased from Fluka Chemie (Sigma-Aldrich, St. Louis, MO, USA). Cyanuric chloride activated mPEG (C-mPEG; 5 kDa) was purchased from Sigma. Bifunctional PEG derivatives, polyethylene glycol-bis-benzotriazolyl carbonate (BTC-PEG-BTC) and the succinimidyl ester of polyethylene glycolbis-propionic acid (SPA-PEG-SPA) (PEG of 3.4 kDa), were obtained from Shearwater Polymers. Derivatives were used without further puri¢cation or purity assessment. Derivatives from Shearwater were s 95% pure. C-mPEG had 6 1% free cyanuric chloride present.
PEG derivatization
Erythrocytes were modi¢ed either as whole blood or as washed cells at a 12% or a 20% hematocrit as previously described [4, 10] . Brie£y, stock solutions of PEG derivatives were made in 50 mM dibasic potassium phosphate, 105 mM NaCl, pH 8.0 (PEG bu¡-er). Overall mPEG concentrations ranged from 0 mM to 7.5 mmol/l. Derivatization reactions were carried out at room temperature for either 30 min or 1 h according to the reactivity of the derivative. Modi¢ed RBC were then washed three times with saline. Control groups consisted of both untreated saline washed RBC and RBC incubated in mPEG-free PEG bu¡er (0 mM mPEG-RBC).
Anti-A antibody-mediated RBC agglutination
This assay was used to assess the ability of attached mPEG to inhibit anti-A antibody-mediated agglutination. Brie£y, 450 Wl of control or pegylated RBC (blood type A) suspensions (6% hematocrit in isotonic saline) were placed in an aggregometer cuvette at 37 ‡C, with stirring, and 20 Wl of anti-A typing serum (or pooled human antiserum) was added. RBC aggregation was then followed over time using a platelet aggregometer as previously described [4] .
Cell^cell interaction
In vitro and in vivo, RBC self-associate giving rise to RBC 'stacks' (Rouleaux formation). In turn, this Rouleaux formation underlies the sedimentation rate used clinically. To assess this natural cell^cell interaction, sedimentation rate and Rouleaux formation were measured for control and PEGylated RBC. For analysis of sedimentation rate, control and mPEG-RBC were suspended to a 40% hematocrit in autologous plasma and loaded into erythrocyte sedimentation tubes (Winpette, Fisher Scienti¢c, Pittsburgh, PA, USA). RBC sedimentation rate was then monitored over a 5 h period. Simultaneously, aliquots of the control and mPEG-derivatized RBC were mixed with equal amounts of either autologous plasma or a 1% saline-bu¡ered dextran solution (dextran molecular mass V500 kDa, from Pharmacia, Uppsala, Sweden) (to induce Rouleaux formation) and examined microscopically for Rouleaux formation.
In vivo survival of mPEG-modi¢ed RBC
To evaluate the e¡ects of the various mPEG derivatives in vivo, RBC survival studies were performed in Balb/c mice. RBC were collected from donor mice via cardiac bleed and derivatized with BTC-mPEG (20 kDa) as previously described [4, 5] . The concentration of mPEG used for the in vivo studies ranged from 0 to 2 mmol/l since murine RBC are physically smaller (i.e. have fewer surface binding sites for mPEG) and more fragile than human RBC. Murine RBC were labeled using the £uo-rescent, membrane anchored marker PKH-26 (Sigma). Blood samples from recipient mice were followed until the labeled RBC were cleared from circulation (approx. 40^50 days for unmodi¢ed syngeneic cells). Survival of £uorescently labeled mPEGtreated and control RBC was monitored by analyzing the percentage of £uorescently labeled RBC by £ow cytometry. A minimum of ¢ve mice were used for each mPEG concentration tested.
Biophysical determinations
To directly measure the e¡ects of linker chemistry and polymer size, biophysical comparisons of the control and mPEG-derivatized RBC were done via partitioning in an aqueous two-phase polymer system and particle electrophoresis. These techniques have been used previously to monitor the consequences of PEG derivatization of proteins and the incorporation of PEG into liposomes [11^13] . Similarly, these techniques have also been extensively used to study erythrocyte surface properties [14, 15] . Partitioning in an aqueous two-phase polymer system (which forms due to the immiscibility of the two polymers: PEG and dextran) exploits the a⁄nity of PEG-RBC for the PEG-rich upper phase. Unmodi¢ed as well as poorly derivatized RBC remain at the interface or within the dextran layer. Particle electrophoresis measures the mobility of particles (e.g. RBC) in an applied electric ¢eld. PEG-mediated changes to the RBC surface are detected as a reduction in electrophoretic mobility due to the camou£age of RBC surface charge and the increased drag force of the polymer itself.
Partitioning
Partitioning of control and PEG-modi¢ed RBC was carried out in an aqueous two-phase system consisting of PEG8000 (Sigma) and dextran T500 (molecular mass V500 kDa; Pharmacia). The two-phase system denoted (5,4) was prepared as described previously [16, 17] and consisted of 5% (w/w) dextran, 4% (w/w) PEG, 0.15 M NaCl, 6.84 mM Na 2 HPO 4 , and 3.16 mM NaH 2 PO 4 (pH 7.4). PEG and dextran stock solution concentrations were determined by refractive index measurements. Phase systems were made up in 50 ml polypropylene tubes and allowed to equilibrate overnight at room temperature. The upper (PEG-rich) phase was drawn o¡ into a separate tube and the lower (dextran-rich) phase was obtained by puncturing the tube to collect the solution. Phase systems were used within 3 days. Control and PEG-RBC were labeled with 51 Cr to allow for quantitation. The partitioning experiment was performed in duplicate and consisted of the addition of 12 Wl (load) of 51 Cr-RBC (3.7U10 8 /ml) to 0.75 ml each of the upper and lower phases. Tubes were inverted 20 times and the phases were allowed to equilibrate and separate at room temperature for 20 min. Aliquots (350 Wl) from both phases were removed for Q-counting. Results were expressed as the percentage of 51 Cr-RBC in the upper phase relative to the total 51 Crlabeled cells added to the system.
Particle electrophoresis
Mobility measurements for control and PEG-RBC were made using the Rank Mark I electrophoresis apparatus equipped with a horizontal microscope with a water immersion lens [13, 18] . Ten di¡erent RBC were chosen randomly and were timed to determine their velocity in the electric ¢eld. The electrophoretic mobility was determined as: mobility = velocity of the particle (Wm/s)/electric ¢eld strength (E) in V/cm, where E = (voltage/distance between the electrodes).
Results
As previously reported, at immunoprotective levels of derivatization, all of the monofunctional mPEG moieties yielded morphologically normal RBC as assessed by both microscopic and Coulter counter analysis (data not shown; [4, 5, 19] ). This ¢nding was observed following mPEG derivatization of both washed RBC and whole blood RBC. Only at relatively high concentrations ( s 2 mmol/l) of derivatization with BTC-mPEG 20 kDa did the cells appear slightly crenated. In contrast, the bifunctional derivatives proved to be less useful for our purposes since signi¢cant, spontaneous, aggregation of the RBC resulted due to cross-linking of individual RBC.
Initial studies examined the di¡erential e¡ects of modifying whole blood versus washed RBC. Not surprisingly, since whole blood contains large amounts of competing derivatization substrates (lymphocytes, plasma proteins, and platelets), derivatization was more e⁄cient using washed RBC versus whole blood at equimolar C-mPEG concentrations. As shown in Fig. 1A , type A RBC agglutination was inhibited to a greater extent following derivatization of washed RBC as compared with derivatized whole blood.
The direct relationship between the RBC:mPEG derivative ratio, the e⁄cacy of linker chemistry, the extent of cell modi¢cation, and the e¡ect of polymer size was evident following two-phase partitioning. Following extensive studies, a (5,4) (dextran, PEG) system was found to be ideal for assessing and com- paring changes in RBC membrane derivatization. In this two-phase system, only about 1% of unmodi¢ed RBC partition to the upper PEG-rich phase while V65% remain at the PEG^dextran interface and 34% are in the dextran-rich phase. As expected, the transition of RBC from the interface/dextran layer to the PEG-rich upper phase was a function of mPEG derivative concentration, protein concentration (washed RBC versus whole blood), and cell number (hematocrit) (Fig. 1B) . While 77% of modi¢ed washed RBC (12% hematocrit) partitioned into the upper PEG phase following derivatization with 1.2 mmol/l, only 19% of RBC from whole blood were observed in the PEG-rich layer. Indicative of the relationship between mPEG derivative concentration per RBC, modi¢cation of higher hematocrits of washed RBC yielded progressively lowered partitioning into the PEG-rich layer. For example, derivatization of a 20% hematocrit with 1.2 mmol/l C-mPEG resulted in 38% of the RBC partitioning to the upper PEG phase.
The two-phase partitioning system was also employed to assess whether any di¡erences in reaction rates and overall membrane derivatization existed between the three chemical linker agents. As noted in Fig. 2A , C-mPEG more rapidly derivatized RBC when compared to either the BTC-or SPA-mPEGs.
To obtain an upper PEG phase partition of 50% after 30 min of reaction time, less C-mPEG 5 kDa (1.2 mM) was required compared with BTC-or SPAmPEG 5 kDa (1.8 mM). After a 1 h reaction time, less than 0.9 mM C-mPEG was required compared to 1.2 mM BTC-or SPA-mPEG 5 kDa to give an upper PEG phase partition of 50% (Fig. 2B) . The greater reactivity of C-mPEG was also demonstrated via microaggregometry in that less C-mPEG (e.g. 0.6 mmol/l C-mPEG 5 kDa versus 1.2 mmol/l BTC-or SPA-mPEG 5 kDa) was required to achieve signi¢-cant ( s 50%) inhibition of antiserum-mediated agglutination (data not shown). However, while BTC and SPA-mPEGs react more slowly with RBC than C-mPEG, equivalent partitioning was noted after 1 h of derivatization (Fig. 2B) .
In addition to PEG surface density, the molecular mass of the mPEG derivative also had an enormous e¡ect on RBC surface properties as determined by both partitioning and particle electrophoresis (Figs. 3  and 4 ). Aqueous two-phase partitioning data con¢rmed the very strong mPEG derivative molecular mass e¡ect (Fig. 3) . To achieve V50% partitioning into the upper phase, only 0.3^0.45 mM mPEG 20 kDa (BTC or SPA) was required compared to 1.2 mM mPEG 5 kDa derivatives or 2.5 mM SPAmPEG 2 kDa. To achieve over 80% partitioning into the PEG phase, 0.6 mM SPA/BTC-mPEG 20 kDa or V2 mM SPA/BTC-mPEG 5 kDa or 5 mM SPA-mPEG 2 kDa were required. Assessing the effect of molecular mass in terms of the total number of ethoxy units, slightly more of the 20 kDa PEG derivatives were required to achieve equivalent a⁄n-ity partitioning. The ratio of ethoxy units required for 50% a⁄nity partitioning was V(1:1.2:1.2^1.8) for the PEG 2 kDa (n = 45):PEG 5 kDa (n = 113):PEG 20 kDa (n = 454) respectively, where n is the number of ethoxy units per molecule. To achieve 80% a⁄nity partitioning, the ratio was (1:1:1.2).
These partitioning ¢ndings are of importance since a key clinical requirement for the use of PEGylated RBC in the prevention of alloimmunization will be Table 1 Separation of mPEG-modi¢ed erythrocytes from unmodi¢ed cells is e⁄ciently accomplished via two-phase partitioning the necessity of removing unmodi¢ed or insu⁄ciently modi¢ed RBC. As demonstrated in Table 1 , the twophase partitioning system is ideally suited for this task as mixtures of mPEG-modi¢ed RBC and unmodi¢ed RBC were successfully separated. Following two-phase separation, approx. 90% of mPEGderivatized RBC were readily recovered from the PEG-rich layer by removing the top phase, diluting this phase in saline, then concentrating the RBC by low speed centrifugation. Particle electrophoresis data (Fig. 4) for mPEG-RBC with varying mPEG chain sizes demonstrated that mobility shifts were directly related to the polymer molecular mass. While larger polymers yielded larger shifts in RBC mobility towards zero, smaller polymers yielded small mobility decrements (regardless of the linker used). For example, the loss of approx. 50% of the inherent RBC mobility (i.e. from 31.2 to 30.6 WmWcm/VWs) was achieved by addition of as little as 0.3 mM BTC-mPEG 20 kDa as compared with V2 mM BTC-mPEG 5 kDa (Fig.  4A) . Similarly, only 0.3 mM SPA-mPEG 20 kDa is required versus 2.5 mM SPA-mPEG 5 kDa. Derivatization of RBC with the short SPA-mPEG 2 kDa derivative was insu⁄cient at the highest concentration tested to lower the mobility to 0.6 WmWcm/VWs (Fig. 4B) . Indeed, substantially higher numbers of total ethoxy units were required for the PEG 5 kDa derivatives ((2.1:1), SPA-PEG 5 kDa:SPA-PEG 20 kDa).
In addition to the monofunctional derivatives employed, bifunctional PEG derivatives were also investigated. Fig. 5 demonstrates that RBC surface modi¢cation is readily achieved using the bifunctional BTC-PEG 3.4 kDa-BTC and SPA-PEG 3.4 kDa-SPA compounds. Electrophoretic mobility shifts for RBC modi¢ed with these bifunctional derivatives were, as might be expected, between those for the monofunctional 5 kDa and 2 kDa SPA-mPEGs (Figs. 5A and 4A). Whether RBC were modi¢ed with BTC-or SPA-PEG bifunctional derivatives, mobility pro¢les were comparable. Similarly, twophase partitioning patterns for the bifunctional PEG 3.4 kDa-derivatized RBC were indistinguishable from one another (Fig. 5B) . Unexpectedly, however, the bifunctional derivatives actually enhanced antiserum-mediated aggregation (Fig. 5C ). Due to the presence of the two linker groups, a high degree Fig. 5 . Modi¢cation of RBC with bifunctional PEG derivatives adversely a¡ects the RBC. RBC (washed and at a 12% hematocrit) were modi¢ed with the bifunctional BTC-PEG-BTC or SPA-PEG-SPA derivatives. In both cases the polymer size was 3.4 kDa. (A) As expected by the polymer size, the shift in electrophoretic mobility of the bifunctional mPEG derivatives was intermediate between the 2 and 5 kDa SPA-mPEG. However, it was observed microscopically during these studies that a signi¢cant percentage of the cells were aggregated together do to PEG cross-linking. (B) Grafting of the bifunctional PEG polymers to the RBC membrane resulted in the expected partitioning of the modi¢ed RBC to the PEG-rich phase. (C) The e¡ect of RBC cross-linking and microaggregate formation due to the bifunctional derivatives was apparent in RBC aggregation studies. As shown, both the SPA-PEG-SPA and BTC-PEG-BTC bifunctional derivatives (5 mM derivatization concentration) actually enhanced type A RBC aggregation in response to anti-A serum. In contrast, the monofunctional BTC-mPEG (5 mM) completely inhibited antiserum-mediated agglutination under the same conditions. Consequent to these studies, the use of these bifunctional derivatives was discontinued. Symbols for panels A and B show the mean data for three experiments þ 1 S.D., each done in duplicate. Microaggregation data are representative of three independent assays. Derivatized RBC shown were modi¢ed with 5.0 mM of the PEG derivative indicated.
of RBC-RBC cross-linkage was noted. Indeed, microscopic analysis conducted during the particle electrophoresis studies demonstrated numerous small aggregates of RBC.
The e¡ect of linker chemistry and polymer size on Rouleaux formation and sedimentation rate was also assessed. Microscopic examination of the modi¢ed RBC demonstrated that cell^cell interactions were disrupted consequent to mPEG derivatization. This is graphically observed via Rouleaux formation in which RBC self-aggregate to form stacks of cells. As shown in Fig. 6 , normal, unmodi¢ed RBC readily form Rouleaux structures in the presence of dextran. In contrast, mPEG modi¢cation inhibits the cell^cell interactions required for Rouleaux formation leading to the random distribution of cells in the microscope ¢eld. Consequent to the loss of Rouleaux formation, erythrocyte sedimentation rate (ESR) is signi¢cantly diminished in a dose-dependent manner. As shown in Fig. 6A , C-mPEG 5 kDa signi¢cantly decreases the ESR as a function of mPEG dose. The loss/delay in sedimentation rate is signi¢-cant (P 6 0.01) even at 0.6 mM of derivatization. However, even at this low derivatization dosage, self-association and sedimentation do occur with Fig. 7 . In vivo survival of mouse mPEG-modi¢ed RBC is normal at immunoprotective levels of derivatization (2 mM) with BTC-mPEG 20 kDa. In vivo survival of mPEG-derivatized mouse RBC is normal even after repeated infusions. Shown are the clearance rates of transfused control and BTC-mPEG 20 kDa-modi¢ed mouse RBC. Survival was followed using a £uo-rescent fatty acid label (PKH-26) as described in Section 2. Each infusion approximated 8^10% of the total mouse RBC mass (based on weight and calculated blood volume). Following each RBC administration, cell clearance was allowed to proceed until no detectable label remained (approx. 50 days). Each time point represents the mean of a minimum of ¢ve Balb/c mice. Murine RBC survival studies utilized both i.v. and i.p. transfusion of the donor cells with no di¡erences in survival kinetics noted between the two modes of administration. Fig. 6 . Increasing polymer size prevents RBC sedimentation and Rouleaux formation. In vitro (in the presence of dextran) and in vivo, RBC self-associate giving rise to RBC 'stacks' (Rouleaux formation). In turn, the Rouleaux formation underlies RBC sedimentation. For analysis of sedimentation rate, control and mPEG-RBC (RBC modi¢ed as washed cells at a 12% hematocrit) were suspended to a 40% hematocrit in autologous plasma and loaded into erythrocyte sedimentation tubes. RBC sedimentation rate was then monitored over a 5 h period. Simultaneously, aliquots of the control and mPEG-derivatized RBC were mixed with equal amounts of either autologous plasma or a 1% saline-bu¡ered dextran solution (to induce Rouleaux formation) and examined microscopically for Rouleaux formation.
time as noted by the di¡erence between 1 and 5 h of sedimentation in the 0.6 mM-modi¢ed RBC. In contrast, subsequent to derivatization with BTC-mPEG 20 kDa, only a minor increase in sedimentation occurs over 5 h of incubation (Fig. 6B) . These latter results clearly demonstrate the e⁄cient disruption of cell^cell (Rouleaux) association by the larger polymers. Surprisingly, in vivo survival studies also demonstrated that BTC-mPEG 20 kDa was vastly superior to the lower molecular mass (5 kDa) C-mPEG derivatives using the exact same modi¢cation conditions. As previously reported by us [5] , C-mPEG 5 kDa derivatization of murine RBC at concentrations v0.6 mM gave rise to signi¢cantly shortened in vivo survival. In part, the loss of viability resulted from the inherently fragile nature of murine RBC. However, modi¢cation of the linker chemistry as well as the use of longer polymers results in signi¢-cantly improved in vivo survival of murine RBC. As ) and MNS (S/s) blood group antigens. The PEG exclusion layer is the physical entity which gives rise to the immunocamou£age of the membrane antigens. The e⁄cacy of the heavily hydrated, neutrally charged, exclusion layer is a function of the length and density of the highly mobile PEG polymer which imparts a space ¢lling (i.e. steric hindrance) cloud around the cell. Indeed, the PEG exclusion layer acts as a molecular size sieve allowing small molecules (e.g. O 2 and glucose) and proteins to e⁄ciently cross while excluding larger proteins (e.g. antibodies). Similarly, the obfuscation of the inherent surface charge (Fig. 4) of the cell membrane by the neutral PEG layer is also of importance in preventing both antibody^antigen interaction and cell^cell interaction. Represented are the relative exclusion layers of 2, 5 and 20 kDa polymers. (B) The Rh antigens are located close to the membrane surface, consequently even relatively short polymers (e.g. 5 kDa) can e¡ectively camou£age these sites. Shown is the immunocamou£age of the Rhc antigen as re£ected by the decrease in mean cell £uorescence. As noted, both 5 kDa polymers similarly camou£aged the Rhc antigen. While increased polymer length (20 kDa) improved the immunocamou£age of the Rh antigens, the e¡ect was moderate. (C) In contrast to the Rh antigens, polymer length was a critical determinant in the immunocamou£age of the MNS and Kidd blood group antigens. As demonstrated, neither 5 kDa polymer resulted in the immunocamou£age of the Jk b antigen. In contrast, the 20 kDa polymer began to exert an e⁄cient immunocamou£age of Jk b .
shown in Fig. 7 , in vivo survival studies using the 20 kDa BTC-mPEG resulted in normal survival kinetics (i.e. V50 days) even at a derivatization concentration of 2 mM. Importantly, these in vivo data demonstrate that normal survival of cells is readily achievable at derivatization concentrations that impart an e¡ective immunocamou£age of human RBC. Furthermore, as demonstrated by our previous studies, PEGylation of murine RBC also does not generate any neoantigens [4, 20] . Finally, we investigated the e¡ects of membrane topography on the e⁄cacy of mPEG-mediated immunocamou£age. Inhibition of antibody binding to Rhc and JK b consequent to mPEG derivatization was assessed via £ow cytometry. While Rhc resides close to the lipid bilayer, JK b is present well above the membrane (Fig. 8) . For Rhc, inhibition of antibody binding was mPEG dose-dependent with increasing chain length (molecular mass) having only a small enhancing e¡ect (Fig. 8B) . In contrast, for antigenic determinants farther out from the lipid bilayer, the 5 kDa mPEGs were completely ine¡ective, regardless of chain density. However, as demonstrated with the 20 kDa BTC-mPEG, with increasing chain length and density, increasing immunocamou£age was observed (Fig. 8C) . These ¢ndings clearly illustrate the importance of antigen topography on the e⁄cacy of immunocamou£age and perhaps indicate why the murine cells derivatized with 20 kDa BTC-mPEG have improved survival when compared to the 5 kDa derivatized cells.
Discussion
Characterizing, quantifying and controlling the biophysical and immunological consequences of mPEG derivatization of RBC are vital for the successful application of this novel technology in transfusion medicine. To this end, the biophysical and biological e⁄cacy of three di¡erent chemical linkers with di¡erent polymer lengths (molecular mass) was assessed via particle electrophoresis, aqueous twophase partitioning, sedimentation rate and in vivo survival.
The chemical linkers used to activate the mPEG (C-, BTC-, and SPA-mPEG) for covalent binding of the polymer to proteins all preferentially target the O-amino group of exposed lysine residues on membrane proteins. While sharing the same targets, BTCand SPA-mPEGs di¡er from C-mPEG in that they attach mPEG directly to the lysine residue without introducing a bulky linker moiety. Comparison of the mPEG 5 kDa derivatives demonstrated that CmPEG reacted most rapidly but, given appropriate derivatization time (1 h versus 30 min), SPA-and BTC-mPEG-modi¢ed RBC exhibited similar biophysical (particle electrophoresis, phase partitioning) and immunological (inhibition of Rouleaux formation and non-ABO antigen detection) characteristics (Figs. 2^4, 6 and 8) . Hence, any of these monofunctional linkers could be suitable for RBC derivatization in the clinical setting.
Other important ¢ndings relate to the e¡ects of polymer size; i.e. size does matter. Larger polymers were found to more e¡ectively camou£age RBC as demonstrated by both biophysical and immunological measurements. While both particle electrophoresis and partitioning results demonstrated that smaller quantities of the larger PEG derivatives were required to exert signi¢cant PEG-speci¢c e¡ects, particle electrophoresis proved to be more sensitive to PEG derivative molecular mass changes than partitioning. For example, a 4-fold increase in mPEG derivative molecular mass (from 5 kDa to 20 kDa) resulted in the requirement of 7^8 times less mPEG derivative to achieve a 50% shift in cell mobility. In contrast, the same 4-fold increase in the polymer size resulted in only a 3^4-fold decrease in the derivative concentration required to achieve 80% partitioning into the PEG-rich phase.
This heightened e¡ect of mPEG molecular mass demonstrated by particle electrophoresis may also be discussed as a function of the number of ethoxy units. Less than half of the total ethoxy units were required for mPEG 20 kDa derivatives compared to mPEG 5 kDa derivatives to decrease the cell mobility by 50%. The greater inhibition of cell mobility by the large PEGs is likely due to the much greater drag force contributed by the longer polymers. In contrast, in the a⁄nity partitioning system, slightly more of the larger PEGs were required (beyond that required to give an equivalent number of ethoxy units). Since the a⁄nity partitioning of mPEG-RBC into the PEG-rich phase is related to the number of ethoxy units attached, these data may re£ect that fewer of the 20 kDa derivative molecules are attached. This ¢nding was expected as the binding of a few mPEG 20 kDa polymers is likely to sterically inhibit the approach and binding of further molecules over a much larger surface area of the cell. In contrast, the smaller molecular mass mPEG derivatives sterically inhibit over a much smaller membrane surface area thus allowing for the approach and binding of more polymers.
In contrast to the monofunctional mPEG derivatives, bifunctional PEGs were not suitable for RBCPEGylation using current conditions. At the ratios used for modifying RBC, the two bifunctional derivatives, BTC-mPEG 3.4 kDa-BTC and SPA-mPEG 3.4 kDa-SPA, were found to cross-link RBC during the derivatization procedure. This cross-linking e¡ec-tively interfered with the ability of PEG to keep cells apart from one another (which is the key to inhibiting agglutination since the anti-A antibody still binds the type A PEG-modi¢ed RBC [10] ). Consequently, when anti-A antibodies are added in the agglutination reaction, inhibition of the antibody-mediated cell^cell interaction is not seen. Agglutination would also be ampli¢ed due to the pre-existence of small RBC aggregates. We hypothesize that, in some circumstances, these bifunctional PEG derivatives may prove useful if RBC numbers are signi¢cantly reduced (i.e. diluted) to minimize cell^cell cross-linking.
As predicted by these studies, the immunocamou£age of RBC membrane antigens is determined by the number of grafted mPEG molecules, polymer size (i.e. molecular mass), antigen density and antigen topography (i.e. the relative height of the antigen above the membrane surface). These ¢ndings are graphically presented in Fig. 8 . As demonstrated in this ¢gure, antigenic and immunogenic epitopes such as human RhC/c (as well as other Rh antigens; Fig.  8A ,B) which are close to the membrane surface are e¡ectively camou£aged by both short and long chain polymers at low to medium levels of derivatization. Hence, antigens such as RhC that statistically exhibit an approx. 5% risk of alloimmunization after a single transfusion, should show a dramatically decreased risk following RBC PEGylation. In contrast, other antigens such as the Kidd and MNS blood group antigens that extend well above the membrane are less e⁄ciently camou£aged by the short chain polymers but can be e¡ectively hidden by the longer chain polymers (Fig. 8A,C) . To what extent RBC PEGylation will attenuate alloimmunization to these later antigens remains unclear. However, antigenic recognition and immunogenicity are not the same. Importantly with regard to this question, we have previously demonstrated that antibody formation (i.e. immunogenicity) in response to PEGylated allogeneic and xenogeneic RBC in mice is e¡ectively blunted [19] , suggesting that even epitopes far away from the membrane are protected from immunologic presentation consequent to membrane derivatization.
Of equal importance to the potential clinical applications of mPEG-RBC is the e¡ect of PEGylation on cell^cell interactions. As described herein, Rouleaux formation as well as antibody-mediated RBC^RBC interactions were e¡ectively blocked by mPEG modi¢cation. These ¢ndings may have implications with regard to the vasoocclusive events characteristic of sickle cell disease. In sickle cell disease, vasoocclusive events are mediated by the enhanced viscosity and aggregation of abnormal RBC in the small arterioles and capillaries. However, as we have recently demonstrated, PEG-RBC serve as e⁄cient chain breakers during aggregation of unmodi¢ed RBC [19] . Hence, consequent to the PEG exclusion volume, RBC retain better £ow characteristics in the arterioles, resist agglutination, and do not adhere to endothelial surfaces. Indeed, an excellent study by Armstrong et al. [21] clearly demonstrated that mPEG modi¢cation reduces low shear viscosity. This loss of viscosity is clearly due to impaired cell^cell interaction as readily evidenced by the loss of Rouleaux formation and decreased sedimentation rate. Finally, the inhibition of cell^cell interactions (e.g. monocyte^RBC or antigen presenting cell^T lymphocyte) likely underlies the blunted immune response to mPEG-modi¢ed cells since immunorecognition requires both cellĉ ell and cell^antibody interactions for the induction of an e⁄cient immunological response [4, 6] . Finally, a critically important step in the potential clinical utilization of the PEG-RBC is the separation of modi¢ed (i.e. non-immunogenic) from unmodi¢ed/undermodi¢ed (i.e. immunogenic) cells. As demonstrated in this study, the biophysical changes arising from membrane derivatization allow for the rapid and e⁄cient processing and recovery of immunocamou£aged (PEG-modi¢ed) RBC. For example, mixtures of strongly PEGylated cells (2.5 mM PEG 5 kDa or 0.9 mM PEG 20 kDa derivatives) and unmodi¢ed cells were easily and e⁄ciently separated by aqueous two-phase partitioning. mPEG-RBC in the upper, PEG-rich phase were then recovered by diluting the PEG phase in saline (to decrease the viscosity) followed by low speed centrifugation. Importantly, this simple method for separating and recovering PEG-modi¢ed RBC can be readily scaled up to manufacturing proportions as was previously done for enzymes (e.g. phosphorylase, several dehydrogenases) puri¢ed from microorganisms [22] .
In sum, multiple linker molecules (cyanuric chloride, BTC, and SPA) were all e⁄cient at derivatizing RBC membranes with mPEG. No signi¢cant di¡er-ences, other than rate of reaction, were observed between the linker moieties when comparable polymer sizes were assessed via particle electrophoresis, twophase partitioning, and immunological analyses. Both polymer surface density and polymer size signi¢cantly in£uenced the biophysical (electrophoretic mobility, phase partitioning, and cell^cell interaction) and immunological characteristics of modi¢ed RBC. While it was anticipated that larger polymers would achieve better immunocamou£age, we were pleasantly surprised that the larger polymers also exhibited improved in vivo viability at equimolar concentration. Furthermore, these data suggest that the derivatization and puri¢cation of mPEG-RBC can be e⁄ciently and economically done in the Blood Bank setting. Clinical usage of these modi¢ed cells may have tremendous therapeutic advantage in managing sickle cell disease which is aggravated by signi¢cant disparities in non-ABO antigens and vasoocclusive events arising from enhanced cell^cell interactions.
